Baxa Introduces Four New Microfuse® Infusion System Administration Sets
Baxa Corporation announces the addition of four specialty administration sets to the MicroFuse® Syringe Infusion System line. These new sets incorporate a T-site for the convenient administration of coronary vasodilators during myocardial perfusion imaging. Their design resulted from customer feedback on safety and ease of administration for this specialty cardiac application.
Denver, CO, March 17, 2005 --(PR.com)-- Baxa Corporation announces the addition of four specialty administration sets to the MicroFuse® Syringe Infusion System line. These new sets incorporate a T-site for the convenient administration of coronary vasodilators during myocardial perfusion imaging. Their design resulted from customer feedback on safety and ease of administration for this specialty cardiac application.
The new MicroFuse Administration Sets feature an integrated, T-site injection port close to the set outlet. This easy-access port facilitates the addition of a secondary medication during cardiac monitoring procedures, minimizing the opportunity for medication error or the introduction of touch contamination. Prior to their release, the available selection of administration sets was limited. The sets offer needleless ports and are available in several convenient lengths to accommodate different clinical practices.
“Baxa has offered a specialty infuser for vasodilation procedures for many years,” explains Mark Thrasher, Market Manager for IV administration products. “The new sets were developed from discussions with cardiac clinics and their technicians. Providers had very specific input on set length, connector types, and specific configurations. They made it easy to respond with products that addressed specific needs.”
The MicroFuse Rapid Rate Infuser is the most popular device for simple, cost-effective administration of adenosine. The new sets complement Baxa Corporation’s existing product line for pharmacologic stress imaging. MicroFuse Administration Sets have a low prime volume to minimize drug waste. Their integrated Y and T connectors make them safer and more efficient than competitive sets used for this application.
Baxa developed the MicroFuse Rapid Rate Infuser specifically for rapid infusion of adenosine during pharmacologic imaging procedures. To accommodate this specialty application, MicroFuse Rapid Rate Infusers deliver a full syringe dose over approximately six or eight minutes, depending on physician requirements.
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark and Germany; and distribution partners worldwide. Further information is available at www.baxa.com.
###
Contacts:
Marian Robinson, Vice President, Marketing, Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: marian.robinson@baxa.com
Maggie Chamberlin Holben, APR, Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
The new MicroFuse Administration Sets feature an integrated, T-site injection port close to the set outlet. This easy-access port facilitates the addition of a secondary medication during cardiac monitoring procedures, minimizing the opportunity for medication error or the introduction of touch contamination. Prior to their release, the available selection of administration sets was limited. The sets offer needleless ports and are available in several convenient lengths to accommodate different clinical practices.
“Baxa has offered a specialty infuser for vasodilation procedures for many years,” explains Mark Thrasher, Market Manager for IV administration products. “The new sets were developed from discussions with cardiac clinics and their technicians. Providers had very specific input on set length, connector types, and specific configurations. They made it easy to respond with products that addressed specific needs.”
The MicroFuse Rapid Rate Infuser is the most popular device for simple, cost-effective administration of adenosine. The new sets complement Baxa Corporation’s existing product line for pharmacologic stress imaging. MicroFuse Administration Sets have a low prime volume to minimize drug waste. Their integrated Y and T connectors make them safer and more efficient than competitive sets used for this application.
Baxa developed the MicroFuse Rapid Rate Infuser specifically for rapid infusion of adenosine during pharmacologic imaging procedures. To accommodate this specialty application, MicroFuse Rapid Rate Infusers deliver a full syringe dose over approximately six or eight minutes, depending on physician requirements.
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark and Germany; and distribution partners worldwide. Further information is available at www.baxa.com.
###
Contacts:
Marian Robinson, Vice President, Marketing, Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: marian.robinson@baxa.com
Maggie Chamberlin Holben, APR, Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
Contact
Baxa Corporation
Marian Robinson
800.567.2292 ext. 2157 or 303.617.2157
http://www.baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
Marian Robinson
800.567.2292 ext. 2157 or 303.617.2157
http://www.baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
Contact
Categories